Goldman Sachs upgraded Amgen to Conviction Buy from Buy with a $350 price target. The move is part of the firm’s “US Conviction List – Directors’ Cut” for March. The analyst believes Amgen is well positioned to add multi-billion dollar opportunities to its portfolio through a “robust pipeline” of drugs in development — many of which have key clinical trial read-outs in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- Jefferies biotechnology analyst to hold an analyst/industry conference call
- Amgen opens state-of-the-art biomanufacturing facility in central Ohio
- Amgen to host conference call
- Amgen call volume above normal and directionally bullish
- Amgen downgraded, Enphase upgraded: Wall Street’s top analyst calls